Sigma Planning Corp Has $419,000 Stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Sigma Planning Corp boosted its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 1,455.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 190,441 shares of the biopharmaceutical company's stock after buying an additional 178,200 shares during the period. Sigma Planning Corp owned approximately 0.10% of Esperion Therapeutics worth $419,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. Versor Investments LP acquired a new position in shares of Esperion Therapeutics during the third quarter worth about $44,000. SJS Investment Consulting Inc. acquired a new position in Esperion Therapeutics during the 4th quarter worth approximately $55,000. Summit Wealth Group LLC bought a new position in shares of Esperion Therapeutics during the 3rd quarter worth approximately $66,000. Foundations Investment Advisors LLC grew its stake in shares of Esperion Therapeutics by 48.6% during the 4th quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company's stock worth $66,000 after acquiring an additional 9,872 shares in the last quarter. Finally, J.W. Cole Advisors Inc. acquired a new stake in shares of Esperion Therapeutics in the fourth quarter valued at approximately $66,000. Institutional investors own 47.39% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently commented on ESPR shares. StockNews.com cut shares of Esperion Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, November 15th. Needham & Company LLC reaffirmed a "buy" rating and issued a $6.00 target price on shares of Esperion Therapeutics in a research report on Friday, December 13th. JMP Securities reiterated a "market outperform" rating and set a $4.00 target price (down previously from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. HC Wainwright reissued a "buy" rating and set a $16.00 price target on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. Finally, Cantor Fitzgerald began coverage on Esperion Therapeutics in a research report on Tuesday, December 17th. They set an "overweight" rating and a $8.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $6.75.

Remove Ads

Esperion Therapeutics Stock Performance

ESPR traded down $0.13 on Monday, reaching $1.58. The company had a trading volume of 4,711,789 shares, compared to its average volume of 4,019,822. The stock has a market cap of $310.33 million, a P/E ratio of -2.46 and a beta of 1.01. Esperion Therapeutics, Inc. has a fifty-two week low of $1.57 and a fifty-two week high of $3.94. The company's fifty day moving average is $2.02 and its 200 day moving average is $2.09.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.